Regulus Therapeutics Inc
RGLS7.980USD
+4.610+136.80%
Fechamento 04/30, 16:00（ET）Cotações atrasadas em 15 min
522.69MValor de mercado
PerdaP/L TTM
Mais detalhes de Regulus Therapeutics Inc Empresa
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Informações da empresa
Código da empresaRGLS
Nome da EmpresaRegulus Therapeutics Inc
Data de listagemOct 04, 2012
Fundado em2007
CEOMr. Joseph P. (Jay) Hagan
Número de funcionários34
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço4224 Campus Point Court
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121
Telefone18582026300
Sitehttps://www.regulusrx.com/
Código da empresaRGLS
Data de listagemOct 04, 2012
Fundado em2007
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Ms. Pascale Witz
Ms. Pascale Witz
Independent Director
Independent Director
4.73K
--
Mr. Joseph P. (Jay) Hagan
Mr. Joseph P. (Jay) Hagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Detalhamento da receita
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: dom, 23 de fev
Tempo de atualização: dom, 23 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
Estatísticas dos acionistas
Acionista
Proporção
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
32.76%
Hedge Fund
27.99%
Venture Capital
17.31%
Investment Advisor
7.47%
Individual Investor
2.18%
Research Firm
0.97%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
11.13%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
137
56.09M
84.68%
-6.17M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
2022Q4
92
9.90M
62.22%
-2.24M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Federated Hermes Global Investment Management Corp.
12.85M
19.4%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
6.47M
9.76%
--
--
Dec 31, 2024
Vivo Capital, LLC
5.00M
7.55%
--
--
Dec 31, 2024
Octagon Capital Advisors LP
4.85M
7.32%
+585.10K
+13.72%
Dec 31, 2024
The Vanguard Group, Inc.
3.97M
5.99%
-121.67K
-2.98%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.89M
5.88%
+146.29K
+3.90%
Dec 31, 2024
Point72 Asset Management, L.P.
895.13K
1.35%
+1.37K
+0.15%
Dec 31, 2024
Deep Track Capital LP
3.26M
4.93%
--
--
Dec 31, 2024
Millennium Management LLC
2.19M
3.31%
+900.74K
+69.75%
Dec 31, 2024
Adage Capital Management, L.P.
2.00M
3.02%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Data
Tipo
Proporção
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1